5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular metabolism by consuming S-adenosylmethionine (SAM) — the body's primary methyl donor. By blocking NNMT, 5-Amino-1MQ helps restore normal methyl group availability, which influences gene expression, fat cell differentiation, and energy expenditure through epigenetic mechanisms.

Mechanism of Action

NNMT catalyzes the methylation of nicotinamide (vitamin B3) using SAM, converting it to 1-methylnicotinamide (1-MNA). When NNMT is highly active — as it is in visceral adipose tissue, certain cancer cell lines, and metabolically unhealthy states — it depletes the SAM pool. This SAM depletion has downstream consequences: reduced histone methylation, altered gene expression in adipocytes, and impaired mitochondrial function.

5-Amino-1MQ competitively inhibits NNMT by occupying its active site. The quinolinium scaffold structurally mimics nicotinamide, allowing it to bind with high affinity while the 5-amino group provides selectivity. By inhibiting NNMT, the compound:

- **Restores SAM levels** — replenishing the methyl donor pool for other methylation reactions throughout the cell - **Upregulates NAD⁺ biosynthesis** — sparing nicotinamide for the NAD⁺ salvage pathway, supporting sirtuin activity and mitochondrial function - **Promotes adipocyte browning** — increasing expression of UCP1 (uncoupling protein 1) and other thermogenic markers in white adipose tissue - **Inhibits adipogenesis** — reducing differentiation of pre-adipocytes into mature fat cells - **Enhances energy expenditure** — elevating basal metabolic rate in preclinical models without affecting food intake

Preclinical Research Overview

The foundational research on 5-Amino-1MQ comes largely from work at the University of Texas Southwestern Medical Center and collaborating institutions. Key findings from animal studies include:

**Body composition:** High-fat diet-fed mice treated with 5-Amino-1MQ showed significant reductions in white adipose tissue mass compared to controls, with no change in lean body mass. This fat-selective effect is a key differentiator from many weight-loss compounds that cause lean tissue wasting.

**Metabolic markers:** Treated animals demonstrated improved insulin sensitivity, lower fasting glucose, and favorable lipid profiles. These metabolic improvements occurred alongside the fat loss, suggesting the compound addresses underlying metabolic dysfunction rather than simply reducing caloric balance.

**Thermogenesis:** Gene expression analyses of adipose tissue from treated animals revealed upregulation of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), UCP1, and other brown adipose tissue markers — indicating a "browning" of white fat that increases thermogenic capacity.

**Muscle preservation:** Unlike many caloric restriction mimetics, 5-Amino-1MQ in high-fat diet models preserved skeletal muscle mass and function, a property that may be relevant to body recomposition goals.

**Safety profile:** Acute and short-term toxicity studies have not identified significant organ toxicity at doses effective for metabolic improvement, though long-term safety data in mammals beyond rodents is not yet established.

Research Context and Limitations

It is essential to understand that virtually all published data on 5-Amino-1MQ comes from in vitro cell culture experiments and rodent models. No human clinical trials have been conducted or published. Extrapolating rodent metabolic data to humans is inherently uncertain — compounds frequently show different pharmacokinetics, potency, and safety profiles across species.

The compound is classified as a research chemical, available exclusively for laboratory and scientific research use under Research Use Only (RUO) conditions. It is not approved by the FDA, EMA, or any comparable regulatory body for human therapeutic or diagnostic use.

Pharmacokinetics (Preclinical)

In rodent studies, 5-Amino-1MQ demonstrates:

- **Oral bioavailability:** Meaningful absorption when administered via gavage, making it suitable for oral research administration in animal models - **CNS penetrance:** The small molecular weight and lipophilicity suggest blood-brain barrier penetration, which is relevant to NNMT's role in neurological contexts - **Half-life:** Moderate — supporting once or twice daily dosing in rodent protocols - **Distribution:** Wide tissue distribution, including adipose, liver, and muscle

Human pharmacokinetic data does not exist in published literature.

NNMT in Broader Biology

NNMT is not exclusively a metabolic enzyme. Elevated NNMT expression has been documented in:

- **Multiple cancer types** — ovarian, bladder, colorectal, and others — where it may support tumor growth by modifying the epigenetic landscape and metabolic milieu - **Neurodegenerative disease** — NNMT activity in the brain has been studied in the context of Parkinson's disease, where 1-MNA (its product) may have neuroprotective or neurotoxic roles depending on the model - **Fibrosis** — NNMT activity in fibroblasts has been linked to fibrotic gene expression programs - **Aging biology** — declining NAD⁺ availability with age intersects with NNMT activity; some geroscience researchers study NNMT as a potential longevity target

These broader roles make NNMT inhibition an active area of drug discovery beyond metabolic disease, and 5-Amino-1MQ is a tool compound used by researchers across these domains.

Selectivity and Off-Target Considerations

A key research question for any NNMT inhibitor is selectivity. The nicotinamide-binding pocket shares structural similarities with other methyltransferases, so off-target binding is a meaningful concern. Published data on 5-Amino-1MQ selectivity panels is limited. Researchers should consider:

- **Cross-reactivity with other SAM-dependent methyltransferases:** Theoretical concern given shared substrate pools; not well characterized for 5-Amino-1MQ specifically - **1-MNA modulation:** Reducing 1-MNA production may have effects in tissues where this metabolite serves signaling roles (e.g., vascular biology) - **Species differences:** Rodent NNMT and human NNMT have high sequence homology, but quantitative differences in binding affinity and inhibitor potency are plausible

Comparison to Related Compounds

| Compound | Target | Primary Research Focus | |---|---|---| | 5-Amino-1MQ | NNMT (inhibitor) | Metabolism, adipose biology, oncology | | NAD⁺ precursors (NR, NMN) | NAD⁺ biosynthesis (upstream) | Aging, mitochondrial function | | GLP-1 agonists (semaglutide) | GLP-1R (receptor agonist) | Appetite suppression, glucose control | | BPC-157 | Multimodal (angiogenesis, growth factors) | Tissue repair, gut health | | Metformin | AMPK activator, complex I inhibitor | Diabetes, longevity research |

5-Amino-1MQ occupies a distinct mechanistic niche — it acts upstream of NAD⁺ by preserving the nicotinamide pool rather than directly supplementing NAD⁺ precursors. Some researchers hypothesize synergistic effects with NAD⁺ precursors, though no controlled studies have tested this combination.

Procurement and Purity Considerations

For research purposes, compound purity is critical to experimental reproducibility. When sourcing 5-Amino-1MQ for research:

- Minimum purity of 98% (HPLC verified) is generally expected for in vitro and in vivo research - Third-party certificates of analysis (COAs) with mass spectrometry confirmation help rule out structural isomers - Endotoxin testing is relevant for cell culture work where LPS contamination could confound results - Proper storage conditions (typically desiccated, protected from light) preserve stability

Research Use Only Disclaimer

5-Amino-1MQ is sold exclusively for laboratory research purposes. It is not intended for human or veterinary use, and it has not been evaluated by any regulatory authority for safety or efficacy in humans. Researchers handling this compound should follow appropriate laboratory safety protocols, including relevant biosafety guidelines for small-molecule research chemicals.